secwatch.observer — SEC 8-K summary
======================================

Issuer:     Acurx Pharmaceuticals, Inc. (ACXP)
CIK:        0001736243
Form:       8-K
Filed at:   2021-11-16T23:59:59+00:00
Accession:  0001104659-21-139573
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Acurx Pharma Q3 net loss $4.6M; Phase 2b enrollment underway
------------------------------------------------------------

- Net loss of $4.6M ($0.46/diluted share) for Q3 2021 vs. $1.3M ($0.21) in Q3 2020.
- Cash balance $14.5M as of Sep 30, 2021; R&D spend $1.1M (up from $0.7M) on Phase 2b costs.
- Phase 2b trial for C. difficile infection (ibezapolstat) enrollment started; completion expected Q3 2022.
- Phase 2a data showed 100% clinical cure, 100% sustained cure, beneficial microbiome changes.
- New collaboration with Leiden University to study DNA pol IIIC enzyme mechanism of action.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1736243/000110465921139573/0001104659-21-139573-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1736243/000110465921139573/tm2133025d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-21-139573

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer